MarketLens
Sign Up

Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC)

7 months ago
SHARE THIS ON:

Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC)

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•5 days ago

Celcuity: Stronger Clinical Evidence, Much Lower Valuation

Celcuity retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. Management targets $2.5B peak sales, though base-case models show upside ev...
Stock News•3 months ago

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

SELLAS Life Sciences enters its pivotal REGAL readout with institutional ownership doubled to 36.34%, after new and existing holders increased stakes ahead of the binary event. Passive and index funds...
Stock News•3 months ago

Playing The Biotech Breakout With Insiders

AbCellera Biologics and Alpha Cognition are highlighted for insider buying and revenue growth. ABCL's Phase 2 data for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts, with analyst targe...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•2 hours ago

Stock Market Today, Nov. 4: Amazon Jumps 6% From New Perspective on AWS Growth and AI Strategy Following Election Results

Stock News•2 hours ago

Apple (AAPL)) Price Forecast: Record High Follows Dramatic Reversal

Stock News•2 hours ago

Apple cements its status as tech's biggest heavyweight with the stock's best day in over a year

Stock News•3 hours ago

Here's What a $1,000 Investment in AMD Could Be Worth by 2030